U
ABMD

UBS’s Abiomed Inc ABMD Stock Holding History

UBS’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-35,000
Closed -$667K – 10878
2013
Q3 		$667K Buy
35,000
+34,800
+17,400% +$796K ﹤0.01% 3794
2013
Q2 		$4K Buy
+200
New +$4.02K ﹤0.01% 9460

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

UBS's ABMD Position: Q3 2014 in Review

UBS reduced its Abiomed Inc (ABMD) stake by 0.24% in Q3 2014, selling an estimated $583 and leaving 9,546 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #5016.

UBS first reported a position in ABMD in Q2 2013 and has held it in 6 quarters since. The position peaked at $241K in Q2 2014. 137 funds tracked by Wall St. Rank hold ABMD as of Q3 2014.

  • UBS held 9,546 shares of Abiomed Inc worth $237K as of Q3 2014.
  • UBS sold 23 Abiomed Inc shares in Q3 2014, an estimated $583.
  • Abiomed Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5016 holding.
  • UBS first reported a position in Abiomed Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Abiomed Inc position peaked at $241K in Q2 2014.
  • 137 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.